We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Amgen (AMGN) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Amgen (AMGN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.73 per share, reflecting a decline of 3.5% compared to the same period last year. Revenues are forecasted to be $8.49 billion, representing a year-over-year increase of 4.2%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Amgen metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Product Sales- Ultra Rare products- Total' of $156.34 million. The estimate indicates a change of -12.7% from the prior-year quarter.
Analysts expect 'Product Sales- TEZSPIRE- Total' to come in at $426.02 million. The estimate points to a change of +49.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Product Sales- KRYSTEXXA- Total' should come in at $290.49 million. The estimate indicates a change of +23.1% from the prior-year quarter.
Analysts predict that the 'Product Sales- TEPEZZA- Total' will reach $429.30 million. The estimate points to a change of +12.7% from the year-ago quarter.
Analysts forecast 'Product Sales- BLINCYTO- U.S.' to reach $294.01 million. The estimate suggests a change of +7.7% year over year.
The consensus among analysts is that 'Product Sales- KYPROLIS- ROW' will reach $105.77 million. The estimate indicates a change of -2.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales- Repatha- U.S.' should arrive at $440.08 million. The estimate indicates a year-over-year change of +28.3%.
The combined assessment of analysts suggests that 'Product Sales- Repatha- ROW' will likely reach $373.03 million. The estimate indicates a change of +19.2% from the prior-year quarter.
It is projected by analysts that the 'Product Sales- BLINCYTO- ROW' will reach $120.48 million. The estimate points to a change of +24.2% from the year-ago quarter.
The consensus estimate for 'Product Sales- KYPROLIS- U.S.' stands at $221.85 million. The estimate points to a change of +2.7% from the year-ago quarter.
Analysts' assessment points toward 'Product Sales- XGEVA- ROW' reaching $150.23 million. The estimate points to a change of -27.1% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- XGEVA- U.S.' at $244.60 million. The estimate indicates a change of -32.1% from the prior-year quarter.
Over the past month, shares of Amgen have returned -1.2% versus the Zacks S&P 500 composite's +9.3% change. Currently, AMGN carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Amgen (AMGN) Q1 Earnings, Beyond Revenue and EPS
In its upcoming report, Amgen (AMGN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.73 per share, reflecting a decline of 3.5% compared to the same period last year. Revenues are forecasted to be $8.49 billion, representing a year-over-year increase of 4.2%.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Amgen metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Product Sales- Ultra Rare products- Total' of $156.34 million. The estimate indicates a change of -12.7% from the prior-year quarter.
Analysts expect 'Product Sales- TEZSPIRE- Total' to come in at $426.02 million. The estimate points to a change of +49.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Product Sales- KRYSTEXXA- Total' should come in at $290.49 million. The estimate indicates a change of +23.1% from the prior-year quarter.
Analysts predict that the 'Product Sales- TEPEZZA- Total' will reach $429.30 million. The estimate points to a change of +12.7% from the year-ago quarter.
Analysts forecast 'Product Sales- BLINCYTO- U.S.' to reach $294.01 million. The estimate suggests a change of +7.7% year over year.
The consensus among analysts is that 'Product Sales- KYPROLIS- ROW' will reach $105.77 million. The estimate indicates a change of -2.1% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales- Repatha- U.S.' should arrive at $440.08 million. The estimate indicates a year-over-year change of +28.3%.
The combined assessment of analysts suggests that 'Product Sales- Repatha- ROW' will likely reach $373.03 million. The estimate indicates a change of +19.2% from the prior-year quarter.
It is projected by analysts that the 'Product Sales- BLINCYTO- ROW' will reach $120.48 million. The estimate points to a change of +24.2% from the year-ago quarter.
The consensus estimate for 'Product Sales- KYPROLIS- U.S.' stands at $221.85 million. The estimate points to a change of +2.7% from the year-ago quarter.
Analysts' assessment points toward 'Product Sales- XGEVA- ROW' reaching $150.23 million. The estimate points to a change of -27.1% from the year-ago quarter.
The average prediction of analysts places 'Product Sales- XGEVA- U.S.' at $244.60 million. The estimate indicates a change of -32.1% from the prior-year quarter.
View all Key Company Metrics for Amgen here>>>Over the past month, shares of Amgen have returned -1.2% versus the Zacks S&P 500 composite's +9.3% change. Currently, AMGN carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .